David G. Armstrong, DPM, MD, PhD
Early concerns from the CANVAS trial linked canagliflozin to an increased risk of lower-extremity amputation, but nearly a decade of additional evidence has reshaped the conversation. David G. Armstrong, DPM, MD, PhD, discusses what...
Early concerns from the CANVAS trial linked canagliflozin to an increased risk of lower-extremity amputation, but nearly a decade of additional evidence has reshaped the conversation. David G. Armstrong, DPM, MD, PhD, discusses what...
Early concerns from the CANVAS...
